LMU Munich and ExpreS2ion Biotechnologies Enter a Licensing Agreement
News Feb 24, 2015
ExpreS2ion Biotechnologies has announced the signature of a research license agreement to provide the Gene Center at Ludwig-Maximilians-Universität München with access to its Drosophila Schneider-2 cell-based technology platform - ExpreS2 - for recombinant protein production.
The stable, non-lytic protein expression platform, which is fully cGMP compatible, will complement the existing capabilities in protein expression at the Gene Center. The platform will be used to address expression of complex and “challenging” proteins, including antibody fragments and other proteins.
This license fits with ExpreS2ion Biotechnologies’ vision of making its protein expression system available to top academic centers globally, as one of the standard protein production platforms for research and development in the areas of immunotherapy and therapeutic proteins.
Dr. Charlotte Dyring, CEO of ExpreS2ion Biotechnologies, said: “We are excited to sign this license agreement with the Gene Center at Ludwig-Maximilians-Universität München, a center of excellence for research into genome maintenance and the regulation of gene expression at all levels. The ExpreS2 protein expression system can respond effectively to the high demands in protein quality and quantity of structural biology projects, and it enables successful production of antibodies and antibody fragments that might fail to express in alternative systems. The Gene Center has been testing the ExpreS2 system for protein production, with very satisfying results”.
Professor Dr. Karl-Peter Hopfner, Professor at the Gene Center at Ludwig-Maximilians-Universität München commented: “We want to understand the molecular and structural mechanisms how the cellular DNA repair and antiviral RNA sensing protein machineries detect, signal and repair or remove malignant nucleic acids such as damaged DNA and viral RNA. The ExpreS2 system complements our tool-box of protein expression systems successfully, allowing us to generate the proteins and antibody-based tools we require, to advance our research”.
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018